20 results on '"Mehta, Shamir R."'
Search Results
2. Complete Revascularization with Multivessel PCI for Myocardial Infarction
- Author
-
Mehta, Shamir R, Wood, David A, Storey, Robert F, Mehran, Roxana, Bainey, Kevin R, Nguyen, Helen, Meeks, Brandi, Di Pasquale, Giuseppe, López-Sendón, Jose, Faxon, David P, Mauri, Laura, Rao, Sunil V, Feldman, Laurent, Steg, P Gabriel, Avezum, Álvaro, Sheth, Tej, Pinilla-Echeverri, Natalia, Moreno, Raul, Campo, Gianluca, Wrigley, Benjamin, Kedev, Sasko, Sutton, Andrew, Oliver, Richard, Rodés-Cabau, Josep, Stanković, Goran, Welsh, Robert, Lavi, Shahar, Cantor, Warren J, Wang, Jia, Nakamya, Juliet, Bangdiwala, Shrikant I, Cairns, John A, COMPLETE Trial Steering Committee and Investigators, Guedes, Antoine, UCL - (MGD) Service de cardiologie, and UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Coronary Artery Disease ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Revascularization ,NO ,law.invention ,Coronary artery disease ,Cardiovascular death ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Randomized controlled trial ,Recurrence ,law ,Internal medicine ,Culprit lesion ,Myocardial Revascularization ,Secondary Prevention ,medicine ,Humans ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Aged ,business.industry ,CONTENEDORES ,Percutaneous coronary intervention ,General Medicine ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,3. Good health ,surgical procedures, operative ,Cardiovascular Diseases ,Conventional PCI ,Purinergic P2Y Receptor Antagonists ,Cardiology ,ST Elevation Myocardial Infarction ,Female ,Stents ,business ,Follow-Up Studies - Abstract
BACKGROUND\ud \ud In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion reduces the risk of cardiovascular death or myocardial infarction. Whether PCI of nonculprit lesions further reduces the risk of such events is unclear.\ud \ud \ud \ud METHODS\ud \ud We randomly assigned patients with STEMI and multivessel coronary artery disease who had undergone successful culprit-lesion PCI to a strategy of either complete revascularization with PCI of angiographically significant nonculprit lesions or no further revascularization. Randomization was stratified according to the intended timing of nonculprit-lesion PCI (either during or after the index hospitalization). The first coprimary outcome was the composite of cardiovascular death or myocardial infarction; the second coprimary outcome was the composite of cardiovascular death, myocardial infarction, or ischemia-driven revascularization.\ud \ud \ud \ud RESULTS\ud \ud At a median follow-up of 3 years, the first coprimary outcome had occurred in 158 of the 2016 patients (7.8%) in the complete-revascularization group as compared with 213 of the 2025 patients (10.5%) in the culprit-lesion-only PCI group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.91; P=0.004). The second coprimary outcome had occurred in 179 patients (8.9%) in the complete-revascularization group as compared with 339 patients (16.7%) in the culprit-lesion-only PCI group (hazard ratio, 0.51; 95% CI, 0.43 to 0.61; P
- Published
- 2019
3. Ticagrelor with or without Aspirin in High-Risk Patients after PCI
- Author
-
Mehran, Roxana, primary, Baber, Usman, additional, Sharma, Samin K., additional, Cohen, David J., additional, Angiolillo, Dominick J., additional, Briguori, Carlo, additional, Cha, Jin Y., additional, Collier, Timothy, additional, Dangas, George, additional, Dudek, Dariusz, additional, Džavík, Vladimír, additional, Escaned, Javier, additional, Gil, Robert, additional, Gurbel, Paul, additional, Hamm, Christian W., additional, Henry, Timothy, additional, Huber, Kurt, additional, Kastrati, Adnan, additional, Kaul, Upendra, additional, Kornowski, Ran, additional, Krucoff, Mitchell, additional, Kunadian, Vijay, additional, Marx, Steven O., additional, Mehta, Shamir R., additional, Moliterno, David, additional, Ohman, E. Magnus, additional, Oldroyd, Keith, additional, Sardella, Gennaro, additional, Sartori, Samantha, additional, Shlofmitz, Richard, additional, Steg, P. Gabriel, additional, Weisz, Giora, additional, Witzenbichler, Bernhard, additional, Han, Ya-ling, additional, Pocock, Stuart, additional, and Gibson, C. Michael, additional
- Published
- 2019
- Full Text
- View/download PDF
4. Ticagrelor in Patients with Stable Coronary Disease and Diabetes
- Author
-
Steg, P. Gabriel, primary, Bhatt, Deepak L., additional, Simon, Tabassome, additional, Fox, Kim, additional, Mehta, Shamir R., additional, Harrington, Robert A., additional, Held, Claes, additional, Andersson, Marielle, additional, Himmelmann, Anders, additional, Ridderstråle, Wilhelm, additional, Leonsson-Zachrisson, Maria, additional, Liu, Yuyin, additional, Opolski, Grzegorz, additional, Zateyshchikov, Dmitry, additional, Ge, Junbo, additional, Nicolau, José C., additional, Corbalán, Ramón, additional, Cornel, Jan H., additional, Widimský, Petr, additional, and Leiter, Lawrence A., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Refining Antithrombotic Therapy for Atrial Fibrillation and Acute Coronary Syndromes or PCI
- Author
-
Mehta, Shamir R., primary
- Published
- 2019
- Full Text
- View/download PDF
6. Sharing Data from Cardiovascular Clinical Trials — A Proposal
- Author
-
Academic Research Organization Consortium for Continuing Evaluat, Patel, Manesh R, Armstrong, Paul W, Bhatt, Deepak L, Braunwald, Eugene, Camm, A John, Fox, Keith AA, Harrington, Robert A, Hiatt, William R, James, Stefan K, Kirtane, Ajay J, Leon, Martin B, Lincoff, A Michael, Mahaffey, Kenneth W, Mauri, Laura, Mehran, Roxana, Mehta, Shamir R, Montalescot, Gilles, Nicholls, Stephen J, Perkovic, Vlado, Peterson, Eric D, Pocock, Stuart J, Roe, Matthew T, Sabatine, Marc S, Sekeres, Mikkael, Solomon, Scott D, Steg, Gabriel, Stone, Gregg W, Van de Werf, Frans, Wallentin, Lars, White, Harvey D, Gibson, Michael, Amsterdam Cardiovascular Sciences, and Vascular Medicine
- Subjects
medicine.medical_specialty ,Biomedical Research ,MEDLINE ,Alternative medicine ,Information Dissemination ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,General & Internal Medicine ,Academic Research Organization Consortium for Continuing Evaluation of Scientific Studies--Cardiovascular (ACCESS CV) ,medicine ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Clinical Trials as Topic ,business.industry ,Medicine (all) ,Periodicals as Topic ,Cardiovascular Diseases ,Editorial Policies ,11 Medical And Health Sciences ,General Medicine ,Clinical trial ,business - Published
- 2016
7. Balancing Thrombotic Events and Bleeding in Primary PCI
- Author
-
Mehta, Shamir R., primary
- Published
- 2013
- Full Text
- View/download PDF
8. Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment
- Author
-
Paré, Guillaume, primary, Mehta, Shamir R., additional, Yusuf, Salim, additional, Anand, Sonia S., additional, Connolly, Stuart J., additional, Hirsh, Jack, additional, Simonsen, Katy, additional, Bhatt, Deepak L., additional, Fox, Keith A.A., additional, and Eikelboom, John W., additional
- Published
- 2010
- Full Text
- View/download PDF
9. Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction
- Author
-
Cantor, Warren J., primary, Fitchett, David, additional, Borgundvaag, Bjug, additional, Ducas, John, additional, Heffernan, Michael, additional, Cohen, Eric A., additional, Morrison, Laurie J., additional, Langer, Anatoly, additional, Dzavik, Vladimir, additional, Mehta, Shamir R., additional, Lazzam, Charles, additional, Schwartz, Brian, additional, Casanova, Amparo, additional, and Goodman, Shaun G., additional
- Published
- 2009
- Full Text
- View/download PDF
10. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes
- Author
-
Mehta, Shamir R., primary, Granger, Christopher B., additional, Boden, William E., additional, Steg, Philippe Gabriel, additional, Bassand, Jean-Pierre, additional, Faxon, David P., additional, Afzal, Rizwan, additional, Chrolavicius, Susan, additional, Jolly, Sanjit S., additional, Widimsky, Petr, additional, Avezum, Alvaro, additional, Rupprecht, Hans-Jurgen, additional, Zhu, Jun, additional, Col, Jacques, additional, Natarajan, Madhu K., additional, Horsman, Craig, additional, Fox, Keith A.A., additional, and Yusuf, Salim, additional
- Published
- 2009
- Full Text
- View/download PDF
11. Dosing of Clopidogrel and Aspirin in Acute Coronary Syndromes.
- Author
-
Mehta, Shamir R., Eikelboom, John W., and Yusuf, Salim
- Subjects
- *
LETTERS to the editor , *CLOPIDOGREL , *TREATMENT of acute coronary syndrome - Abstract
A response by Shamir R. Mehta, John W. Eikelboom, and Salim Yusuf to letters to the editor about their article "The CURRENT-OASIS 7 Investigators. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes" in the September 2, 2010 issue is presented.
- Published
- 2010
- Full Text
- View/download PDF
12. Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment.
- Author
-
Paré, Guillaume, Mehta, Shamir R., Yusuf, Salim, Anand, Sonia S., Connolly, Stuart J., Hirsh, Jack, Simonsen, Katy, Bhatt, Deepak L., Fox, Keith A. A., and Eikelboom, John W.
- Subjects
- *
CLOPIDOGREL , *METABOLITES , *RANDOMIZED controlled trials , *PLACEBOS , *NUCLEOTIDES , *ATRIAL fibrillation , *PATIENTS - Abstract
Background: It has been suggested that clopidogrel may be less effective in reducing the rate of cardiovascular events among persons who are carriers of loss-of-function CYP2C19 alleles that are associated with reduced conversion of clopidogrel to its active metabolite. Methods: We genotyped patients from two large, randomized trials that showed that clopidogrel, as compared with placebo, reduced the rate of cardiovascular events (the primary efficacy outcome) among patients with acute coronary syndromes and among patients with atrial fibrillation. Patients were genotyped for three single-nucleotide polymorphisms (*2, *3, *17) that define the major CYP2C19 alleles. Results: Among 5059 genotyped patients with acute coronary syndromes, clopidogrel as compared with placebo significantly reduced the rate of the primary efficacy outcome, irrespective of the genetically determined metabolizer phenotype (P=0.12 for heterogeneity). The effect of clopidogrel in reducing the rate of the primary efficacy outcome was similar in patients who were heterozygous or homozygous for loss-of-function alleles and in those who were not carriers of the alleles (rate among carriers, 8.0% with clopidogrel vs. 11.6% with placebo; hazard ratio with clopidogrel, 0.69; 95% confidence interval [CI], 0.49 to 0.98; rate among noncarriers, 9.5% vs. 13.0%; hazard ratio, 0.72; 95% CI, 0.59 to 0.87). In contrast, gain-of-function carriers derived more benefit from clopidogrel treatment as compared with placebo than did noncarriers (rate of primary outcome among carriers, 7.7% vs. 13.0%; hazard ratio, 0.55; 95% CI, 0.42 to 0.73; rate among noncarriers, 10.0% vs. 12.2%; hazard ratio, 0.85; 95% CI, 0.68 to 1.05; P=0.02 for interaction). The effect of clopidogrel on bleeding did not vary according to genotypic subgroups. Among 1156 genotyped patients with atrial fibrillation, there was no evidence of an interaction with respect to either efficacy or bleeding between the study treatment and the metabolizer phenotype, loss-of-function carrier status, or gain-of-function carrier status. Conclusions: Among patients with acute coronary syndromes or atrial fibrillation, the effect of clopidogrel as compared with placebo is consistent, irrespective of CYP2C19 loss-of-function carrier status. (Funded by Sanofi-Aventis and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00249873.) N Engl J Med 2010;363:1704-14. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
13. Complete Revascularization with Multivessel PCI for Myocardial Infarction.
- Author
-
Mehta, Shamir R., Wood, David A., and Cairns, John A.
- Published
- 2020
- Full Text
- View/download PDF
14. Acute Coronary Syndromes.
- Author
-
Mehta, Shamir R., Yusuf, Salim, and Granger, Christopher
- Subjects
- *
LETTERS to the editor , *CORONARY disease - Abstract
A response by Shamir R. Mehta, Salim Yusuf and Christopher Granger to a letter to the editor about their article "Early Versus Delayed Invasive Intervention in Acute Coronary Syndromes" in the May 21, 2009 issue is presented.
- Published
- 2009
- Full Text
- View/download PDF
15. CYP2C19 Genotype and Outcomes of Clopidogrel Treatment.
- Author
-
Paré, Guillaume, Mehta, Shamir R., and Eikelboom, John W.
- Subjects
- *
LETTERS to the editor , *GENOTYPE-environment interaction - Abstract
A response by Guillaume Paré, Shamir R. Mehta and John W. Eikelboom to letters to the editor about their article "Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment" in the October 28, 2010 issue is presented.
- Published
- 2011
- Full Text
- View/download PDF
16. Treatment of Acute Coronary Syndromes.
- Author
-
Yusuf, Salim and Mehta, Shamir R.
- Subjects
- *
LETTERS to the editor , *HEART diseases - Abstract
A letter to the editor is presented in response to the study "Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE)," focusing on the effects of clopidogrel with aspirin in patients with acute coronary syndromes published in the August 16, 2001 issue.
- Published
- 2002
- Full Text
- View/download PDF
17. Venous Thromboembolism and Cancer.
- Author
-
Eikelboom, John W. and Mehta, Shamir R.
- Subjects
- *
LETTERS to the editor , *THROMBOEMBOLISM , *PATIENTS - Abstract
A letter to the editor is presented in response to the article "Incidence of Cancer After Prophylaxis With Warfarin Against Recurrent Venous Thromboembolism," by S. Schulman and P. Lindmarker, previously published in the June 29, 2000 issue of the "New England Journal of Medicine."
- Published
- 2000
- Full Text
- View/download PDF
18. Sharing Data from Cardiovascular Clinical Trials--A Proposal.
- Author
-
Patel MR, Armstrong PW, Bhatt DL, Braunwald E, Camm AJ, Fox KA, Harrington RA, Hiatt WR, James SK, Kirtane AJ, Leon MB, Lincoff AM, Mahaffey KW, Mauri L, Mehran R, Mehta SR, Montalescot G, Nicholls SJ, Perkovic V, Peterson ED, Pocock SJ, Roe MT, Sabatine MS, Sekeres M, Solomon SD, Steg G, Stone GW, Van de Werf F, Wallentin L, White HD, and Gibson M
- Subjects
- Humans, Periodicals as Topic standards, Biomedical Research standards, Cardiovascular Diseases, Clinical Trials as Topic standards, Editorial Policies, Information Dissemination
- Published
- 2016
- Full Text
- View/download PDF
19. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
- Author
-
Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, and Yusuf S
- Subjects
- Acute Coronary Syndrome mortality, Acute Coronary Syndrome therapy, Aged, Angioplasty, Balloon, Coronary, Aspirin adverse effects, Cardiovascular Diseases mortality, Cardiovascular Diseases prevention & control, Clopidogrel, Combined Modality Therapy, Coronary Angiography, Coronary Artery Bypass, Double-Blind Method, Female, Hemorrhage chemically induced, Hemorrhage mortality, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction epidemiology, Platelet Aggregation Inhibitors adverse effects, Research Design, Stroke epidemiology, Ticlopidine administration & dosage, Ticlopidine adverse effects, Acute Coronary Syndrome drug therapy, Aspirin administration & dosage, Platelet Aggregation Inhibitors administration & dosage, Ticlopidine analogs & derivatives
- Abstract
Background: Clopidogrel and aspirin are widely used for patients with acute coronary syndromes and those undergoing percutaneous coronary intervention (PCI). However, evidence-based guidelines for dosing have not been established for either agent., Methods: We randomly assigned, in a 2-by-2 factorial design, 25,086 patients with an acute coronary syndrome who were referred for an invasive strategy to either double-dose clopidogrel (a 600-mg loading dose on day 1, followed by 150 mg daily for 6 days and 75 mg daily thereafter) or standard-dose clopidogrel (a 300-mg loading dose and 75 mg daily thereafter) and either higher-dose aspirin (300 to 325 mg daily) or lower-dose aspirin (75 to 100 mg daily). The primary outcome was cardiovascular death, myocardial infarction, or stroke at 30 days., Results: The primary outcome occurred in 4.2% of patients assigned to double-dose clopidogrel as compared with 4.4% assigned to standard-dose clopidogrel (hazard ratio, 0.94; 95% confidence interval [CI], 0.83 to 1.06; P=0.30). Major bleeding occurred in 2.5% of patients in the double-dose group and in 2.0% in the standard-dose group (hazard ratio, 1.24; 95% CI, 1.05 to 1.46; P=0.01). Double-dose clopidogrel was associated with a significant reduction in the secondary outcome of stent thrombosis among the 17,263 patients who underwent PCI (1.6% vs. 2.3%; hazard ratio, 0.68; 95% CI, 0.55 to 0.85; P=0.001). There was no significant difference between higher-dose and lower-dose aspirin with respect to the primary outcome (4.2% vs. 4.4%; hazard ratio, 0.97; 95% CI, 0.86 to 1.09; P=0.61) or major bleeding (2.3% vs. 2.3%; hazard ratio, 0.99; 95% CI, 0.84 to 1.17; P=0.90)., Conclusions: In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke. (Funded by Sanofi-Aventis and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00335452.)
- Published
- 2010
- Full Text
- View/download PDF
20. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
- Author
-
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, and Fox KA
- Subjects
- Aged, Angina, Unstable mortality, Angina, Unstable therapy, Angioplasty, Balloon, Coronary, Anticoagulants adverse effects, Enoxaparin adverse effects, Female, Fondaparinux, Hemorrhage chemically induced, Humans, Male, Middle Aged, Myocardial Infarction mortality, Myocardial Infarction therapy, Polysaccharides adverse effects, Recurrence, Stroke, Survival Analysis, Treatment Outcome, Angina, Unstable drug therapy, Anticoagulants therapeutic use, Enoxaparin therapeutic use, Myocardial Infarction drug therapy, Polysaccharides therapeutic use
- Abstract
Background: The combined use of anticoagulants, antiplatelet agents, and invasive coronary procedures reduces ischemic coronary events but also increases bleeding in patients with acute coronary syndromes. We therefore assessed whether fondaparinux would preserve the anti-ischemic benefits of enoxaparin while reducing bleeding., Methods: We randomly assigned 20,078 patients with acute coronary syndromes to receive either fondaparinux (2.5 mg daily) or enoxaparin (1 mg per kilogram of body weight twice daily) for a mean of six days and evaluated death, myocardial infarction, or refractory ischemia at nine days (the primary outcome); major bleeding; and their combination. Patients were followed for up to six months., Results: The number of patients with primary-outcome events was similar in the two groups (579 with fondaparinux [5.8 percent] vs. 573 with enoxaparin [5.7 percent]; hazard ratio in the fondaparinux group, 1.01; 95 percent confidence interval, 0.90 to 1.13), satisfying the noninferiority criteria. The number of events meeting this combined outcome showed a nonsignificant trend toward a lower value in the fondaparinux group at 30 days (805 vs. 864, P=0.13) and at the end of the study (1222 vs. 1308, P=0.06). The rate of major bleeding at nine days was markedly lower with fondaparinux than with enoxaparin (217 events [2.2 percent] vs. 412 events [4.1 percent]; hazard ratio, 0.52; P<0.001). The composite of the primary outcome and major bleeding at nine days favored fondaparinux (737 events [7.3 percent] vs. 905 events [9.0 percent]; hazard ratio, 0.81; P<0.001). Fondaparinux was associated with a significantly reduced number of deaths at 30 days (295 vs. 352, P=0.02) and at 180 days (574 vs. 638, P=0.05)., Conclusions: Fondaparinux is similar to enoxaparin in reducing the risk of ischemic events at nine days, but it substantially reduces major bleeding and improves long term mortality and morbidity. (ClinicalTrials.gov number, NCT00139815.)., (Copyright 2006 Massachusetts Medical Society.)
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.